Long-Term Follow Up of VOY-101 Non-nAMD Extension Study

Long-Term Follow Up of VOY-101 for Advanced Non-Neovascular Age-Related Macular Degeneration Extension Study

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07660640

Acronym

OASIS

Enrollment

Registered

2026-06-22

Start date

2026-03-03

Completion date

2031-08-30

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration

Keywords

Long term follow up, extension study

Brief summary

Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration

Detailed description

This is a long-term observational, non-interventional extension study to the Phase 1/2a studies that administered VOY-101 to subjects with advanced non-neovascular age-related macular degeneration (AMD).

Interventions

OTHERobservational study

No intervention - observational study

BIOLOGICALVOY-101

One-time intravitreal injection of VOY-101.

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Have received an injection of VOY-101 and exited either the PBI-AMD-001 or PBI-AMD-002 Phase 1/2a study of VOY-101. 2. Are willing and able to understand and provide informed consent.

Exclusion criteria

There are no

Design outcomes

Primary

Measure	Time frame	Description
Frequency of ocular and systemic VOY-101 related AEs	3 years	Frequency of ocular and systemic VOY-101 related AEs (serious \[SAEs\] and treatment-emergent non-serious adverse events \[TEAEs\]).

Countries

Israel, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 23, 2026